Quick Answer
BIOADAPTIVES, INC. reported Cash and Equivalents of $25.4 thousand for fiscal year 2022.
BIOADAPTIVES, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $25.4K | -69.4% |
| 2021 | $82.9K | +1708.1% |
| 2020 | $4.6K | -62.7% |
| 2019 | $12.3K | -78.1% |
| 2018 | $56.2K | +56682.8% |
| 2015 | $99.00 | -99.7% |
| 2014 | $37.9K | +103.5% |
| 2013 | $18.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $17.9K | — | -78.4% |
| December 31, 2021 | $82.9K | +1708.1% | +242.3% |
| March 31, 2021 | $24.2K | +108.0% | +428.1% |
| December 31, 2020 | $4.6K | -62.7% | -68.3% |
| September 30, 2020 | $14.4K | +9221.9% | +261.3% |
| June 30, 2020 | $4.0K | -66.3% | -65.7% |
| March 31, 2020 | $11.6K | — | -5.4% |
| December 31, 2019 | $12.3K | -78.1% | +7843.9% |
- BIOADAPTIVES, INC. showed a decrease of -69.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2022 period, BIOADAPTIVES, INC.’s cash and equivalents has grown by 36.5% (from $18.6 thousand to $25.4 thousand).
- The most recent figure is from BIOADAPTIVES, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 31, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: